JPMorgan Initiates 'Overweight' Rating on CRISPR Therapeutics

Summary

JPMorgan has given CRISPR Therapeutics an ‘overweight’ rating for the first time, with a target price of $70. Analyst Brian Cheng highlights CRISPR’s unique advantages in gene editing and its portfolio nearing several key development milestones. The company’s collaboration with Vertex Pharmaceuticals on the Casgevy therapy and its autoimmune CAR-T candidates offer faster market entry paths, particularly in cardiovascular targets, presenting attractive growth opportunities.Zhitong+ 2

Impact Analysis

So basically, JPMorgan’s ‘overweight’ rating on CRISPR Therapeutics is a significant endorsement, especially as it’s their first. Analyst Brian Cheng points to CRISPR’s unique position in gene editing and its strategic milestones, like the Casgevy therapy and autoimmune CAR-T candidates, which offer faster market entry, particularly in cardiovascular targets. This is a strong signal of confidence in CRISPR’s growth trajectory, especially with a $70 target price. The interesting part isn’t just the rating but the timing—right as CRISPR is hitting key development milestones and has strong cash reserves of $2 billion. This suggests JPMorgan sees a near-term inflection point. Market’s missing that this isn’t just about gene editing; it’s about strategic positioning and execution. Watch for how competitors respond and any shifts in institutional holdings, especially given recent mixed analyst ratings and significant stock movements.Zhitong+ 4